Welcome from Claire Hermsen, MD PGY3 Ophthalmology Resident Hello! My name is Claire, and I am a PGY3 ophthalmology resident at the University of Wisconsin. I chose ophthalmology because, during medical school, I loved all …
Karo Barsamian
GALLOP
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
ABID Study
This is a prospective, cross-sectional, multi-center, observational study to collect and develop a meticulously curated and diverse AMD benchmark dataset, featuring reference standard level 1 classification and comprehensive annotation of images.
CLARICO
A Phase 1/2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients with Primary Photoreceptor Disease
LUGANO
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept(Eylea) in Subjects with Wet AMD
WHOLE EYE OCT
To examine posterior eye shape changes in childhood myopia and progressive nearsightedness using whole eye optical coherence tomography (OCT) imaging.
CLARITY
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
LUNA
B-421a-006 is a 24-month, double-masked, randomized, sham-controlled, multicenter study to evaluate the safety, tolerability, and efficacy of ultevursen in subjects with RP due to mutations in exon 13 of the USH2A gene.
Nanoparticles subdue antibiotic-resistant bacteria’s defences while enhancing innate immunity
A method for overcoming antibiotic resistance uses multimodal nanoparticles that target bacterial defence mechanisms while enhancing the innate immune response. The rise in antibiotic resistance is considered a slow-moving medical catastrophe, as these revolutionary drugs that have kept us relatively safe from bacterial infection for decades are losing their efficacy. In part due to their co-evolution, bacterial pathogens have developed mechanisms to resist almost every antibiotic on the market and we are in desperate need for new, innovative approaches. Writing in Nature Nanotechnology, Zhu et al. present a nanoparticle-based possibility, in which they target bacterial defence mechanisms while simultaneously enhancing the ability of the host immune cells to fight infection.